Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients?
Meiser
Bruno M
BM
Department of Cardiac Surgery, University of Munich, Grosshadern Medical Center, Marchioninistrasse 15, 81366 Munich, Germany. bruno.meiser@med.uni-muenchen.de
Groetzner
Jan
J
Kaczmarek
Ingo
I
Landwehr
Peter
P
Müller
Markus
M
Jung
Sebastian
S
Uberfuhr
Peter
P
Fraunberger
Peter
P
Stempfle
Hans-Ulrich
HU
Weis
Michael
M
Reichart
Bruno
B
D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000209:etiology; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection; D016027:Heart Transplantation / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D017211:Treatment Failure
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D016559:Tacrolimus